Drug reference
lutetium (177lu) dotatate
Peptide receptor radioligand therapy · Radiopharmaceutical, Antineoplastic agent
Peptide receptor radioligand therapyRadiopharmaceutical, Antineoplastic agentATC V10XX04
CDSCO approvedATC V10XX04
EXCRETION
—
not curated
INTERACTIONS
—
none in our sources
PREGNANCY
—
not curated
Mechanism
Lutetium (177Lu)-DOTA-octreotate (177Lu-dotatate) is a radioligand coupled to a somatostatin analogue. The somatostatin analogue targets and binds to somatostatin receptors expressed on tumor cells. Upon internalization, the radioligand emits both β particles (causing localized cell death) and lower-energy γ particles (allowing imaging), leading to tumor cell cytotoxicity.
Indications
Inoperable, somatostatin receptor-positive midgut neuroendocrine tumors (NETs)Advanced gastroenteropancreatic neuroendocrine tumors (NETs) of higher grade (grade 2 or 3)
Dosing
- Adult
- Four doses administered intravenously every 8 weeks (in NETTER-1 trial).
Side effects
Serious
- Renal toxicity (mitigated with coadministration of intravenous amino acids)
- Acute leukemia (rare)
- Myelodysplastic syndrome (rare)
Related guidelines
Ask House about lutetium (177lu) dotatate
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Harrison 22e·Verified: 2026-05-10 · House clinical team